PRECISION BIOSCIENCES INC
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
DTIL$9.68-8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Changes in Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · TreasuryStock · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance- December 31, 2024 | 8,229,730 | $1 | $539,808 | $(482,464) | $(952) | $56,393 |
| Issuance of common stock under employee stock purchase plan | 30,999 | — | 140 | — | — | $140 |
| Share-based compensation expense | — | — | 2,822 | — | — | $2,822 |
| Issuance of common stock to licensees | 220,712 | — | 1,031 | — | — | $1,031 |
| Issuance of common stock through ATM facility, net of issuance cost | 1,818,886 | — | 9,516 | — | — | $9,516 |
| Settlement of restricted stock units | 275,540 | — | — | — | — | — |
| Net loss | — | — | — | (20,565) | — | $(20,565) |
| Balance- March 31, 2025 | 10,575,867 | $1 | $553,317 | $(503,029) | $(952) | $49,337 |
| Share-based compensation expense | — | — | 2,937 | — | — | 2,937 |
| Issuance of common stock through ATM facility, net of issuance cost | 1,036,488 | — | 5,300 | — | — | 5,300 |
| Settlement of restricted stock units | 51,641 | — | — | — | — | — |
| Net loss | — | — | — | (23,520) | — | (23,520) |
| Balance- June 30, 2025 | 11,663,996 | $1 | $561,554 | $(526,549) | $(952) | $34,054 |
| Share-based compensation expense | — | — | 2,386 | — | — | $2,386 |
| Issuance of common stock under employee stock purchase plan | 18,745 | — | 78 | — | — | 78 |
| Issuance of common stock through ATM facility, net of issuance cost | 382,571 | — | 1,888 | — | — | 1,888 |
| Settlement of restricted stock units | 44,368 | — | — | — | — | — |
| Net loss | — | — | — | (21,772) | — | (21,772) |
| Balance- September 30, 2025 | 12,109,680 | $1 | $565,906 | $(548,321) | $(952) | $16,634 |
| Balance- December 31, 2025 | 24,115,346 | $1 | $621,387 | $(528,188) | $(952) | $92,248 |
| Issuance of common stock under employee stock purchase plan | 23,233 | — | 83 | — | — | 83 |
| Share-based compensation expense | — | — | 1,549 | — | — | 1,549 |
| Issuance of common stock to licensees | 201,504 | — | 662 | — | — | 662 |
| Issuance of common stock from pre-funded warrants | 875,000 | — | — | — | — | — |
| Settlement of restricted stock units | 617,830 | — | — | — | — | — |
| Net loss | — | — | — | (18,441) | — | (18,441) |
| Balance- March 31, 2026 | 25,832,913 | $1 | $623,681 | $(546,629) | $(952) | $76,101 |
| Share-based compensation expense | — | — | 1,844 | — | — | 1,844 |
| Issuance of common stock from pre-funded warrants | 525,000 | — | — | — | — | — |
| Settlement of restricted stock units | 102,660 | — | — | — | — | — |
| Net loss | — | — | — | (32,652) | — | (32,652) |
| Balance- June 30, 2026 | 26,460,573 | $1 | $625,525 | $(579,281) | $(952) | $45,293 |
| Issuance of common stock under employee stock purchase plan | 28,186 | — | 104 | — | — | 104 |
| Share-based compensation expense | — | — | 2,958 | — | — | 2,958 |
| Issuance of common stock through ATM facility, net of issuance costs | 1,408,833 | — | 10,856 | — | — | 10,856 |
| Proceeds from issuance of common stock | 22,488 | — | 150 | — | — | 150 |
| Net loss | — | — | — | (7,586) | — | (7,586) |
| Balance- September 30, 2026 | 27,920,080 | $1 | $639,593 | $(586,867) | $(952) | $51,775 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.